Plasma Natriuretic Peptides As Predictors of Hemodynamically in Children with Congenital Heart Disease

Year 2012, Volume: 4 Issue: 2, 8 - 14, 01.12.2012

Murat Kanğın Ayfer Gözü Pirinççioğlu Ömer Alyan

Abstract

Background: The objects of the study was to investigate the role and importance of N-Terminal Pro-B-Type natriuretic peptide (NT-Pro-BNP) as a biochemical marker in patients with congenital heart disease and to determine if there is any relationship between anthropometric measurements and natriuretic peptide. Method: Forty-five children with CHD (17 cyanotic and 28 acyanotic) and thirty children with normal echocardiography were enrolled in the study. Patients were divided into two groups as cyanotic or acyanotic. Anthropometric measurements including body weight, height, BMI and Zscore(weight) and Z-score(height) and thorough physical examination were recorded on admission. Serum NT-Pro-BNP was also measured Results: Majority of patients in cyanotic and acyanotic groups had tetralogy of fallot and ventricular septal defect, respectively. The mean age was significantly lower in cyanotic patients compared with acyanotic and controls. N-Terminal-Pro-B-Type natriuretic peptide levels were significantly elevated in cyanotic and acyanotic patients compared with controls. N-Terminal-ProBNP was negatively correlated with left ventricular ejection fraction among the echocardiographic parameters (p=0.014, r=-0.364). In acyanotic patients, NT-Pro-BNP was positively correlated with shunt ratio (p=0.029, r=0,428) and Systolic pulmonary arterial pressure (p=0.005, r= 0.519) while it was negatively correlated with Z-score (weight) (p=0.044, r=-0.390). Conclusion N-Terminal-pro-BNP is one of essential serum markers for cardiac disease and it could be used to predict the severity and prognosis of CHD as a response to ventricular volume expansion and pressure overload

Keywords

Congenital heart disease, brain natriuretic peptide, anthropometric measurements

References

• Hoffman JI, Kaplan S (2002). The incidence of congenital heart disease. J Am Coll Cardiol 39:1890–900.
• Samanek M (2000). Congenital heart malformations: prevalence, severity, survival, and quality of life. Cardiol Young 10:179–85.
• Maisel AS, Mc Cullough PA (2003). Cardiac natriuretic peptides: A proteomic window to cardiac function and clinical management. Rev Cardiovasc Med 4 (Suppl. 4):S3–S12.
• Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R et al. (2002). Utility of B-natriuretic peptide in detecting diastolic dysfunction. Comparison with Doppler velocity recordings. Circulation 105: 595–601.
• Daniels LB, Maisel AS (2007). Natriuretic peptides. J Am Coll Cardiol 50:2357–2368.
• Costello JM, Goodman DM, Green TP (2006). A review of the natriuretic hormone system’s diagnostic and therapeutic potential in critically ill children. Pediatric Critical Care Medicine, 7:308–318.
• Henry WL, DeMaria A, Gramiak R, King DL, Kisslo JA, Popp RL, et al.(1980) Report of the America Society of
• Echocardiography (ASE) committee on nomenclature and standards in two-dimensional echocardiography. Circulation : 212−217. WHO working group (1986) Use and interpretation of anthropometric indicators of nutritional status. Bull World Health Organ 64:929–941.
• Cowie MR, Mendez GF (2002). BNP and congestive heart failure. Prog Cardiovasc Dis 44:293-321.
• Meune C, Fulla Y, Martins E, Bergmann JF, Devaux JY (2003). B-type natriuretic peptide for the diagnostic and prognostic assessment in cardiology: Its interest and perspectives of application. Presse Med 32:181-185.
• McCullough PA, Sandberg KR (2003). Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 14:13
• Davis KM, Fish LC, Minaker KL, Elahi D (1996). Atrial natriuretic peptide levels in the elderly: differentiating normal aging changes from disease. J Gerontol A Biol Sci Med Sci 51:M95–101.
• Luchner A, Burnett JC, Jougasaki M, Hense HW, Heid IM, Muders F, et al (2000). Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 18:1121–1128.
• Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett Jr JC (2002). Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40:976–982.
• Koch A, Singer H (2003). Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart (8):875–878.
• Koulouri S, Acherman RJ, Wong PC, Chan LS, Lewis AB (2004). Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol (4):341–346.
• Christenson RH, Azzazy HME, Duh SH, Maynard S, Seliger SL, deFilippi CR (2010) Impact of Increased Body
• Mass Index on Accuracy of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP for Diagnosis of Decompensated Heart Failure and Prediction of All-Cause Mortality. Clin Chem 56 633-641. Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL et al.(2005). Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department Substudy. Am Heart J 149:744-750.
• Mandeep RM, Patricia AU, Myung HP, Robert LS, Hector OV, Bobbett CH et al. (2004) Obesity and suppressed B- type natriuretic peptide levels in heart failure. J Am Coll Cardiol 43:1590-1595.
• Trimarchi H, Muryan A, Campolo-Girard V, Dicugno M, Barucca N, Lombi F et al. (2011) Elevated Pro-Brain
• Natriuretic Peptide, Troponin T and Malnutrition Inflammatory Score in Chronic Hemodialysis Patients with Overt Cardiovascular Disease. Nephron Clin Pract 117:198-205
• Kjaer A, Hildebrandt P, Appel J, Petersen CL (2005). Neurohormones as markers of rightand left-sided cardiac dimensions and function in patients with untreated chronic heart failure. Int J Cardiol 99:301-306.
• Wei T, Zeng C, Chen L, Chen Q, Zhao R, Lu G, et al. (2005) Bedside tests of B-type natriuretic peptide in the diagnosis of left ventricular diastolic dysfunction in hypertensive patients. Eur J Heart Fail 7:75-79.
• Tsapenko MV, Tsapenko AV, Comfere TB, Mour GK, Mankad SV, Gajic O (2008) Arterial pulmonary hypertension in noncardiac intensive care unit. Vasc Health Risk Manag 4:1043–1060.
• Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al. (2006) Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 48:2546–
• Keysser G, Schwerdt C, Taege C (2008) Right-heart failure after right heart catheterization in a patient with scleroderma and suspected pulmonary hypertension. Rheumatol Int 28:1269–1271